These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1191 related articles for article (PubMed ID: 14584004)

  • 1. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2004; 2003(3):CD004094. PubMed ID: 15266516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.
    Padwal R; Li SK; Lau DC
    Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1437-46. PubMed ID: 12975638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Posch N; Meschik J; Semlitsch T
    Cochrane Database Syst Rev; 2016 Mar; 3():CD007654. PubMed ID: 26934640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term changes in blood pressure following orlistat and sibutramine treatment: a meta-analysis.
    Johansson K; Sundström J; Neovius K; Rössner S; Neovius M
    Obes Rev; 2010 Nov; 11(11):777-91. PubMed ID: 20025693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.
    García Díaz E; Martín Folgueras T
    Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of weight-reducing drugs in people with hypertension.
    Siebenhofer A; Winterholer S; Jeitler K; Horvath K; Berghold A; Krenn C; Semlitsch T
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD007654. PubMed ID: 33454957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A; Horvath K; Jeitler K; Berghold A; Stich AK; Matyas E; Pignitter N; Siering U
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007654. PubMed ID: 19588440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.
    Viner RM; Hsia Y; Tomsic T; Wong IC
    Obes Rev; 2010 Aug; 11(8):593-602. PubMed ID: 19922432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight management and current options in pharmacotherapy: orlistat and sibutramine.
    Leung WY; Thomas GN; Chan JC; Tomlinson B
    Clin Ther; 2003 Jan; 25(1):58-80. PubMed ID: 12637112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
    Norris SL; Zhang X; Avenell A; Gregg E; Schmid CH; Lau J
    Cochrane Database Syst Rev; 2005 Jan; 2005(1):CD004096. PubMed ID: 15674929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis.
    Johansson K; Neovius K; DeSantis SM; Rössner S; Neovius M
    Obes Rev; 2009 Sep; 10(5):564-75. PubMed ID: 19460116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A; Jeitler K; Horvath K; Berghold A; Siering U; Semlitsch T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007654. PubMed ID: 23543553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interventions for the treatment of obesity in children and adolescents.
    Mead E; Atkinson G; Richter B; Metzendorf MI; Baur L; Finer N; Corpeleijn E; O'Malley C; Ells LJ
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD012436. PubMed ID: 27899001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orlistat and sibutramine beyond weight loss.
    Mannucci E; Dicembrini I; Rotella F; Rotella CM
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):342-8. PubMed ID: 17928208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term pharmacotherapy for obesity.
    Klein S
    Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO
    MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of orlistat in the management of obesity.
    O'Meara S; Riemsma R; Shirran L; Mather L; ter Riet G
    Health Technol Assess; 2001; 5(18):1-81. PubMed ID: 11399238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.